| 751 | 5 | 55 |
| 下载次数 | 被引频次 | 阅读次数 |
腺相关病毒的安全与长效特点,使其成为基因治疗中最有前景的病毒载体之一。虽然第一个以该病毒为载体的基因药物Glybera已在欧盟获批上市,然而如何进一步提高载体的靶向性与产品纯度仍是当务之急。腺相关病毒的受体是介导病毒与靶细胞结合的分子基础,其与病毒的结合具有很强的特异性,因此相关受体的研究不仅有助于改善基因治疗的靶向性,亦能为高纯度病毒的亲和纯化带来希望。目前已有11种腺相关病毒的受体被发现,本文就其受体的发现过程、结构特点、功能应用等方面展开综述,为今后相关研究提供一些思路。
Abstract：The adeno-associated virus has become one of the most promising viral vectors in gene therapy and appears to have excellent safety and long-term effectiveness.The first gene therapy drug,Glybera,which is based on the adeno-associated virus has been approved in the European Union.However,the targeting ability and purification process of the adeno-associated virus are still need to be improved.The receptors of the adeno-associated virus lay a molecular basis for the binding to its target cell specifically.Therefore,advances in the science of the receptors of the adeno-associated virus will not only enhance their targeting therapy performance,it will also improve their affinity-purification process.To date,11 receptors of the adeno-associated virus have been reported.Accordingly,their discovery,structure,function and applications are reviewed here to aid future researches.
[1]Weitzman M D,Linden R M.Adeno-associated virus biology[J].Methods Mol Biol,2011,807:801-823.
[2]许瑞安,唐明青,刁勇,王明席,王启钊.腺相关病毒-从病毒到临床[M].北京:科学出版社,2014:1-204.
[3]C Summerford,R J Samulski.Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2virions[J].Virol,1998,72(2):1438-1445.
[4]Asokan A,Hamra J B,Govindasamy L,Agbandje-McKenna M,Samulski R J.Adeno-associated virus type 2contains an integrin alpha5beta1binding domain essential for viral cell entry[J].Virol,2006,80(18):8961-8969.
[5]Levy H C,Bowman V D,Govindasamy L,McKenna R,Nash K,Warrington K,Chen W,Muzyczka N,Yan X,Baker T S,Agbandje-McKenna M.Heparin binding induces conformational changes in Adeno-associated virus serotype 2[J].Struct Biol,2009,165(3):146-156.
[6]Asokan A,Conway J C,Phillips J L,Li C,Hegge J,Sinnott R,Yadav S,DiPrimio N,Nam H J,Agbandje-McKenna M,McPhee S,Wolff J,Samulski R J.Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle[J].Nat Biotechnol,2010,28(1):79-82.
[7]Ng R,Govindasamy L,Gurda B L,McKenna R,Kozyreva O G,Samulski R J,Parent K N,Baker T S,Agbandje-McKenna M.Structural characterization of the dual glycan binding adeno-associated virus serotype 6[J].Virol,2010,84(24):12945-12957.
[8]Gerlach B,Kleinschmidt J A,Bottcher B,Conformational changes in adeno-associated virus type 1induced by genome packaging[J].J Mol Biol,2010,409(3):427-438
[9]Schmidt M,Govindasamy L,Afione S,Kaludov N,Agbandje-McKenna M,Chiorini J A.Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate AAV(VR-942)[J].Virol,2008,82(17):8911-8916.
[10]Halbert C L,A.J,Miller A D.Adeno-associated virus type 6(AAV6)vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2vectors[J].Virol,2001,75(14):6615-6624.
[11]Mietzsch M,Broecker F,Reinhardt A,Seeberger P H,Heilbronn R.Differential adeno-associated virus serotype-specific interaction patterns with synthetic heparins and other glycans[J].Virol,2014,88(5):2991-3003.
[12]Kaludov N,Brown K E,Walters R W,Zabner J,Chiorini J A.Adeno-associated virus serotype 4(AAV4)and AAV5both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity[J].Virol,2001,75(15):6884-6893.
[13]Walters R W,Yi S M,Keshavjee S,Brown K E,Welsh M J,Chiorini J A,Zabner J.Binding of adenoassociated virus type 5to 2,3-linked sialic acid is required for gene transfer[J].J Biol Chem,2001,276(23):20610-20616.
[14]Z Wu,E Miller,M Agbandjemckenna,R J Samulski.α2,3andα-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1and6[J].Virol,2006,88(18):9093-9103.
[15]McLean J R,Smith G A,Rocha E M,Hayes M A,Beagan J A,Hallett P J,Isacson O2.Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection[J].Neurosci Lett,2014,576:73-78.
[16]Bell CL1,Vandenberghe LH,Bell P,Limberis MP,Gao GP,Van Vliet K,Agbandje-McKenna M,Wilson JM.The AAV9receptor and its modification to improve in vivo lung gene transfer in mice[J].J Clin Invest,2011,21(6):2427-2435.
[17]Bell C L,Gurda B L,Van Vliet K,Agbandje-McKenna M,Wilson J M.Identification of the galactose binding domain of the adeno-associated virus serotype 9capsid[J].Virol,2012,86(13):7326-7333.
[18]Shen S,Bryant K D,Brown S M,Randell S H,Asokan A.Terminal N-linked galactose is the primary receptor for adeno-associated virus 9[J].J Biol Chem,2011,286(15):13532-13540.
[19]Geoghegan J C,Keiser N W,Okulist A,Martins I,Wilson M S,Davidson B L.Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo[J].Mol Ther Nucleic Acids,2014,3:2162-2531.
[20]Summerford C,Bartlett J S,Samulski R J.αVβ5integrin:a co-receptor for adeno-associated virus type 2infection[J].Nat Med,1999,5:78-82.
[21]Akache B,Grimm D,Pandey K,Yant S R,Xu H,Kay M A.The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8,2,3,and 9[J].Virol,2006,80(19):9831-9836.
[22]Di Pasquale G,Davidson B L,Stein C S,Martins I,Scudiero D,Monks A,Chiorini J A.Identification of PDGFR as a receptor for AAV-5transduction[J].Nat Med,2003,9(10):1306-1312.
[23]Qing K,Mah C,Hansen J,Zhou S,Dwarki V,Srivastava A.Human fibroblast growth factor receptor 1is a co-receptor for aav2co-receptor[J].Nat Am,1999,5:71-77.
[24]Kashiwakura Y,Tamayose K,Iwabuchi K,Hirai Y,Shimada T,Matsumoto K,Nakamura T,Watanabe M,Oshimi K,Daida H.Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2infection[J].Virol,2005,79(1):609-614.
[25]Ling C,Lu Y,Kalsi J K,Jayandharan G R,Li B,Ma W,Cheng B,Gee S W,McGoogan K E,Govindasamy L,Zhong L,Agbandje-McKenna M,Srivastava A.Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3[J].Hum Gene Ther,2010,21(12):1741-1747.
[26]Weller M L,Amornphimoltham P,Schmidt M,Wilson P A,Gutkind J S,Chiorini J A.Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6[J].Nat Med,2010,16(6):662-664.
[27]Pillay S,Meyer N L,Puschnik A S,Davulcu O,Diep J,Ishikawa Y,Jae L T,Wosen J E,Nagamine C M,Chapman M S,Carette J E.An essential receptor for adeno-associated virus infection[J].Nature,2016,530(7588):108-112.
[28]Grimm D K A,R K,Kleinschmidt J A.Novel tools for production and purification of recombinant adenoassociated virus vectors[J].Hum Gene Ther,1998,9(18):2745-2760.
[29]Doria M,Ferrara A,Auricchio A.AAV2/8vectors purified from culture medium with a simple and rapid protocol transduce murine liver,muscle,and retina efficiently[J].Hum Gene Ther Methods,2013,24(6):392-398.
[30]Lock M,Alvira M,Vandenberghe L H,Samanta A,Toelen J,Debyser Z,Wilson J M.Rapid,simple,and versatile manufacturing of recombinant adeno-associated viral vectors at scale[J].Hum Gene Ther,2010,21(10):1259-1271.
[31]Castillo K,Valenzuela V,Matus S,Nassif M,Onate M,Fuentealba Y,Encina G,Irrazabal T,Parsons G,Court F A,Schneider B L,Armentano D,Hetz C.Measurement of autophagy flux in the nervous system in vivo[J].Cell Death Dis,2013,4:917
[32]Auricchio A,O'Connor E,Hildinger M,Wilson J M.A single-step affinity column for purification of serotype-5based adeno-associated viral vectors[J].Mol Ther,2001,4(4):372-374.
[33]许瑞安陈凌,肖卫东.分子药物学[M].北京:北京大学医学出版社,2008:2-41.
[34]Arnold G S,Sasser A K,Stachler M D,Bartlett J S.Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes[J].Mol Ther,2006,14(1):97-106.
[35]White S J,Nicklin S A,Büning H,Brosnan M J,Leike K,Papadakis E D,Hallek M,Baker A H.Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors[J].Circulation,2004,109(4):513-519.
[36]WANG Yigang,HUANG Fang.Targeting cancer therapy of adeno-associated virus vector[J].Chin J Cell Biol,2007,29:651-656.
[37]Shi W,H A,Bartlett J S.Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinoma[J].Gynecol Oncol,2006,103(3):1054-1062.
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.003145
中图分类号:R373
引用信息:
[1]王立振,侯莹,成志云,等.腺相关病毒的受体研究进展[J].病毒学报,2017,33(03):462-468.DOI:10.13242/j.cnki.bingduxuebao.003145.
基金信息:
国家自然科学基金(项目号:81271691),题目:可避免转基因产物细胞免疫毒性的重组腺相关病毒载体的构建及评价; 华侨大学科研基金资助项目(项目号:14BS111),题目:高丰度miRNA的小RNA深度测序筛选; 福建省中青年教师教育科研项目(项目号:JA14020),题目:巧妙的从公共深度测序数中遴选高保真miRNA骨架~~
2017-04-18
2017-04-18
2017-04-18